Harlan Robins Sells 386,240 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 386,240 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $22.01, for a total value of $8,501,142.40. Following the transaction, the insider owned 1,019,658 shares in the company, valued at $22,442,672.58. This trade represents a 27.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Trading Down 3.2%

Shares of NASDAQ ADPT opened at $20.16 on Thursday. The stock has a market capitalization of $3.23 billion, a PE ratio of -61.09 and a beta of 2.07. Adaptive Biotechnologies Corporation has a twelve month low of $9.96 and a twelve month high of $22.80. The stock has a fifty day simple moving average of $16.50 and a 200-day simple moving average of $15.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million for the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s revenue was up 35.1% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.20) EPS. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. 1492 Capital Management LLC acquired a new position in Adaptive Biotechnologies during the fourth quarter worth approximately $1,484,000. Jupiter Asset Management Ltd. grew its position in shares of Adaptive Biotechnologies by 33.8% during the fourth quarter. Jupiter Asset Management Ltd. now owns 362,811 shares of the company’s stock worth $5,892,000 after acquiring an additional 91,683 shares during the last quarter. Rhenman & Partners Asset Management AB grew its position in shares of Adaptive Biotechnologies by 22.2% during the fourth quarter. Rhenman & Partners Asset Management AB now owns 605,000 shares of the company’s stock worth $9,825,000 after acquiring an additional 110,000 shares during the last quarter. UBS Group AG increased its holdings in shares of Adaptive Biotechnologies by 101.6% in the 4th quarter. UBS Group AG now owns 511,927 shares of the company’s stock valued at $8,314,000 after acquiring an additional 257,947 shares during the period. Finally, Westfield Capital Management Co. LP acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at $65,942,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ADPT has been the subject of a number of research reports. JPMorgan Chase & Co. dropped their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, May 6th. TD Cowen raised their price target on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Guggenheim upped their price objective on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Finally, Morgan Stanley reduced their price objective on Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, May 12th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average price target of $20.50.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Negative Sentiment: Harlan Robins sold 386,240 shares of Adaptive Biotechnologies, a transaction worth about $8.5 million, which is the most notable insider sale and may signal caution to investors. Article Title
• Negative Sentiment: Susan Bobulsky sold 487 shares, adding to a pattern of insider selling at Adaptive Biotechnologies. Article Title
• Negative Sentiment: Francis Lo sold 44,838 shares and separately sold another 51,004 shares, reinforcing the recent insider selling trend in ADPT. Article Title
• Neutral Sentiment: Recent filings note that these sales were made under pre-arranged 10b5-1 trading plans, which can reduce the significance of the transactions compared with discretionary selling.
• Positive Sentiment: Adaptive Biotechnologies previously posted better-than-expected quarterly results, including revenue growth of 35.1% year over year and EPS that beat estimates, which may help limit downside pressure.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.